Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR07

Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Tanner Buchanan, Pharmacy Intern, University of Rochester Specialty Pharmacy, Rochester, NY

Co-Authors: Shannon Gowen, PharmD, Clinical Pharmacist, and Jerimiah Moore, PharmD, Clinical Pharmacist, University of Rochester Specialty Pharmacy, Rochester, NY

BACKGROUND: Oral anticancer therapy has become an increasingly popular alternative to traditional cancer regimens. As a result, patients have fewer office visits and less medication complications.1 Although oral therapy is more convenient than intravenous therapy, oral medications come with significant financial barriers, which can limit patient access to, and affect the success of, these regimens.1,2 In 2019, pharmacists from the University of Chicago Medical Center published an article in the Journal of Managed Care & Specialty Pharmacy that drew attention to the increasing need for an oncology specialty pharmacy to assist with reduced financial toxicity, by securing copay assistance for patients with cancer.3 They reported the results of their study showing that of 75 patients who received financial assistance, the cost-savings ranged from $5 to $13,138 per prescription claim.3 The high cost burden of oral anticancer medications may result in limited access to therapies, delays in starting treatment, and therapy abandonment.1

OBJECTIVES: To determine the total financial support obtained by University of Rochester Specialty Pharmacy to help relieve patients from financial toxicity associated with oral oncolytic medications, and to determine the percentage of patients receiving copay assistance support, including independent foundations, manufacturer copay cards, and social work funding.

METHOD: This retrospective quality improvement project was granted Institutional Review Board exemption. We reviewed prescription claim data for patients who were prescribed an oral oncolytic through the University of Rochester Wilmot Cancer Institute between July 20, 2020, and July 20, 2021, and filled at our specialty pharmacy. The data were analyzed using descriptive statistics.

RESULTS: Over a 1-year period, a total of 12,310 prescription claims were reviewed for 1746 patients who filled an oral oncolytic through our specialty pharmacy. Of these patients, 932 (53.4%) patients received financial assistance, including 25% of patients who used copay assistance from independent foundation grants, 11.2% who used manufacturer copay cards/vouchers, and 17.2% who received financial support through internal social work funding. After optimizing New York State Epic enrollment, our specialty pharmacy patients received $4,403,513.73 in financial assistance, including $2,704,845.41 that was obtained either from independent grants (38.5%), manufacturer copay card/vouchers (41.8%), or the University of Rochester internal social work funding (19.7%). Before financial assistance was obtained, the average patient copay for foundation/grant, copay card, and social work was $328.65, $1730.70, and $807.05, respectively. After financial assistance was obtained through this project, the average patient copay was $0.80, $46.48, and $96.23, respectively.

CONCLUSION: These relatively low copays with our financial assistance program for high-cost oral anticancer therapy highlight the value that an integrated health-system specialty pharmacy has in the care of patients with cancer when financial assistance is obtained.

  1. Zullig LL, Wolf S, Vlastelica L, et al. The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm. 2017;23:407-411.
  2. Niccolai JL, Roman DL, Julius JM, Nadour RW. Potential obstacles in the acquisition of oral anticancer medications. J Oncol Pract. 2017;13:e29-e36.
  3. Farano JL, Kandah HM. Targeting financial toxicity in oncology specialty pharmacy at a large tertiary academic medical center. J Manag Care Spec Pharm. 2019;25:765-769.
Related Items
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Perceptions of PGY2 Oncology Programs on Financial Toxicity Education and Preparedness
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Pharmacist-Led Oral Chemotherapy Monitoring Pilot Study and Assessment of Patient-Reported Outcomes and Adherence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Chemotherapy
The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Immunotherapy
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.